Biogen 주식 가격. 1BIIB - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

가격

130.75

매수가

130.50

매도가

132.00

거래량

132.00 일간 변동폭 132.00

125.25 52주 범위 220.70

market_cap

19.139B

전일 종가

130.20

개장가

132.00

최근 거래 시간

132

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

발행 주식

146,374,937

배당수익률

주가수익률

12.72

주당순이익(EPS)

11.15

매출

9.68B

순이익

1.63B

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.biogen.com

본부

Wilmington, Delaware, USA

설립됨

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the 이탈리아 증권거래소 with ticker 1BIIB. The last closing price for Biogen was 130.20 €. Over the last year, Biogen shares have traded in a share price range of 125.25 € to 220.70 €.

Biogen currently has 146,374,937 shares in issue. The market capitalisation of Biogen is 19.06 € billion. Biogen has a price to earnings ratio (PE ratio) of 12.72.

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients Global...

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare...

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE...

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Once every four weeks maintenance...

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which...

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0.9	0.693107431652	129.85	132.25	128.8	33	129.55102041	DE
4	-1.25	-0.94696969697	132	145.05	128.8	79	135.82829519	DE
12	-14.85	-10.1991758242	145.6	149.4	125.25	76	138.16587411	DE
26	-50.5	-27.8620689655	181.25	181.25	125.25	58	145.02154119	DE
52	-77.65	-37.2600767754	208.4	220.7	125.25	49	161.21381238	DE
156	-84.85	-39.3552875696	215.6	244.6	125.25	44	166.47093773	DE
260	-84.85	-39.3552875696	215.6	244.6	125.25	44	166.47093773	DE

1BIIB - Frequently Asked Questions (FAQ)

What is the current Biogen share price?

The current share price of Biogen is 130.75 €

How many Biogen shares are in issue?

Biogen has 146,374,937 shares in issue

What is the market cap of Biogen?

The market capitalisation of Biogen is EUR 19.06B

What is the 1 year trading range for Biogen share price?

Biogen has traded in the range of 125.25 € to 220.70 € during the past year

What is the PE ratio of Biogen?

The price to earnings ratio of Biogen is 12.72

What is the cash to sales ratio of Biogen?

The cash to sales ratio of Biogen is 2.15

What is the reporting currency for Biogen?

Biogen reports financial results in USD

What is the latest annual turnover for Biogen?

The latest annual turnover of Biogen is USD 9.68B

What is the latest annual profit for Biogen?

The latest annual profit of Biogen is USD 1.63B

What is the registered address of Biogen?

The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

What is the Biogen website address?

The website address for Biogen is www.biogen.com

Which industry sector does Biogen operate in?

Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
1SPCEVirgin Galactic Holdings Inc	4.0425 € (25.84%)	2.3k
S24IL Sole 24 ORE SpA	0.806 € (16.47%)	616.67k
MOLMoltiply Group	39.75 € (9.81%)	106.17k
EPRBEprcomunicazione spa	1.50 € (8.70%)	98.35k
WRDF25Redelfi SpA	1.39 € (8.29%)	2.66k
WFCH25Franchetti SPA	1.737 € (-29.96%)	50
WS3D25Solid World Group spa	0.08 € (-23.81%)	84.11k
MPTImpianti SpA	1.05 € (-22.22%)	174k
GSRG Rent	0.089 € (-19.09%)	163.5k
U24Ucapital24 Spa	0.562 € (-16.86%)	111.6k
TITTelecom Italia SpA	0.2877 € (-0.90%)	213.87M
ISPIntesa Sanpaolo Spa	4.808 € (-2.83%)	102.43M
ENELEnel Spa	7.242 € (0.89%)	41.73M
SPMSaipem Spa	2.19 € (-0.32%)	34.79M
A2AA2A Spa	2.243 € (-2.86%)	28.64M

9Coastal 5 분 전

I do enjoy your responses. 🙂

GEMZ

mick 5 분 전

not today , he not so good for htoo

HTOO

Whalatane 5 분 전

Comparison and Context ( Groks AI view )
Short-Term Impact: A reverse split might offer a temporary price boost and keep the stock in the game on a major exchange, while pink sheets could lead to an immediate drop in interest and value.

Long-Term Outlook: Success depends on th

UNCY

chen1992 5 분 전

Agreed, all these changes on the eve of the MARAD deadline to issue a DWP license to them? Hmmmmm…

TGLO

learningcurve2020 6 분 전

Seems about right. I’d be surprised if the Island Boys didn’t insist on a reverse split for greater swings??

NWBO

Mark 6 분 전

$DGLY looks like the start of a move here, watch for .072 break and hold

DGLY

LowFloatLopes 6 분 전

I think this is gonna be one that just keeps running for a few days into next week ..might slow down for a day or two and then right as ppl start to forget ..BOOM ..stickin with this one I have a feeling

SAG

BasedOnFeels 6 분 전

Your attempts at engagement on a dead site are the real dumpster fire.
Posting on a trip 0 pink sheet with no liquidity, is the real laughs. "pInK StOcKS dUn sUCk"
ILST lives rent free in your head. "Ooop, havent posted my shitty opinion in awhile, better remind em"
Stick to

ILST

DiscoverGold 6 분 전

$GS $6+ Million ITM Calls All coming in at/above the ask
By: Cheddar Flow | March 20, 2025

• $GS $6M+ ITM Calls

Significant volume spike for this contract today

All coming in at/above the ask.

pbs.twimg.com/media/GmfzDEPawAAWm

DR_rugby 6 분 전

What if he has knowledge of the Algo

And can work with others to reprogram it

Instead of skimming funds and not buying real shares

It does the opposite

Increasing the true value of the property

GLTA

AMC

capgain 6 분 전

The Rolling Stones - Flashpoint - You Cant Always Get What You Want

https://www.youtube.com/watch?v=NSi-Bt8OsGs

PEACHMAN 6 분 전

Read the link dope

https://docs.google.com/viewerng/viewer?url=https://impactfusionbrands.com/wp-content/uploads/SURAEC-Report-Submitted-to-Louisiana-House-Committee-on-Agriculture-02-08-2025.pdf

IFUS

Stockman1010101 7 분 전

Sounds like a good idea plan. Thanks for the explanation.
Good Luck to you friend.

FNMA

georgie18 7 분 전

AGH...Added $1.02...🥳...Still looking for $1.75 plus...

georgie18

Member Level
Re: georgie18 post# 677428

Thursday, March 20, 2025 10:27:34 AM

Post#
677460
of 677525
AGH...85s clearing here...🥳

AGH

exwannabe 7 분 전

I'm going to miss flippers posts. Genuinely
So would I. This board is running low on posters who can attempt a rational conversation and not just scream insults and such.

NWBO

georgie18 8 분 전

AGH

Stockman1010101 8 분 전

Thank you.

FNMA

9Coastal 8 분 전

Recent(s):
MarketScreener
Feb 19, 2025 — MINERALRITETM Corporation has filed FORM 10-12g

Stock Titan
The book value of RITE common stock increased to approximately $.031 per share post-conversion.

The company plans to conduct a Regulation A offer

GEMZ

haha11 8 분 전

UPDATE $SVIX.....10.......21.45...H..Line...

https://schrts.co/DNGqvJde

SVIX

Spyke37 8 분 전

I have an alternate take. The overarching goal here is to work toward a settlement that can be monetized either in a solid valuation for the stock, or a purchase of the company that can be redeemed by shareholders. The RICO, or threat of RICO, seems to have gotten the attention of the defendants.

VPLM

georgie18 8 분 전

AGH

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Biogen Inc (1BIIB)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

Biogen Inc 정보

1BIIB 최신 뉴스

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

1BIIB - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Biogen Inc (1BIIB) 시세

Biogen Inc (1BIIB)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

Biogen Inc 정보

1BIIB 최신 뉴스

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

1BIIB - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거